Modeling the impact of population screening on breast cancer mortality in the United States

Breast

Volumn 20, Issue SUPPL. 3, 2011, Pages

  Mandelblatt, Jeanne S ^a   Cronin, Kathleen A ^b   Berry, Donald A ^c   Chang, Yaojen ^a   de Koning, Harry J ^d   Lee, Sandra J ^e   Plevritis, Sylvia K ^f   Schechter, Clyde B ^g   Stout, Natasha K ^h   van Ravesteyn, Nicolien T ^d   Zelen, Marvin ^e   Feuer, Eric J ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h HARVARD PILGRIM HEALTH CARE   (United States)

Author keywords

Mammography; Modeling; Screening

Indexed keywords

AGE; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; FALSE POSITIVE RESULT; MAMMOGRAPHY; PRIORITY JOURNAL; PROBABILITY; RISK BENEFIT ANALYSIS; SIMULATION; UNITED STATES;

EID: 80054872085     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/S0960-9776(11)70299-5     Document Type: Article

References (39)

1. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002, 359:909-919.
2. Tabar L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am 2000, 38:625-651.
3. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 2006, 368:2053-2060.
4. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan B, Nygren P, et al. Screening for breast cancer: systematic evidence review update for the US preventive services task force. 2009.
5. Mandelblatt JS, Fryback DG, Weinstein MC, Russell LB, Gold MR Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J Gen Intern Med 1997, 12:551-558.
6. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N EnglJ Med 2005, 353:1784-1792.
7. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009, 151:738-747.
8. United States Preventive Services Task Force Screening for Breast Cancer. Agency for Health Care Research and Quality. Rockville, MD Accessed March 11, 2011. http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrca.htm.
9. When evidence collides with anecdote, politics, and emotion: breast cancer screening. Ann Intern Med 2010, 152:531-532.
10. Woloshin S, Schwartz LM The benefits and harms of mammography screening: understanding the trade-offs. JAMA 2010, 303:164-165.
11. Murphy AM Mammography screening for breast cancer: a view from 2 worlds. JAMA 2010, 303:166-167.
12. Woolf SH The 2009 breast cancer screening recommendations of the US Preventive Services Task Force. JAMA 2010, 303:162-163.
13. Kopans D The 2009 U.S. Preventive Services Task Force Guidelines ignore important scientific evidence and should be revised or withdrawn. Radiology 2010, 256(1):15-20.
14. Hendrick RE, Helvie MA United States Preventive Services Task Force screening mammography recommendations: science ignored. AJR Am J Roentgenol 2011, 196:W112-W116.
15. American Cancer Society Guidelines for the Early Detection of Cancer Accessed March 11, 2011. http://www.cancer.org/Healthy/FindCancerEarly/CancerScreeningGuidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer.
16. Cancer Intervention and Surveillance Modeling Network on 15 September 2008. http://cisnet.cancer.gov/breast/profiles.html.
17. Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL The Wisconsin Breast Cancer Epidemiology Simulation Model. j Natl Cancer Inst Monogr 2006, 37-47.
18. Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr 2006, 47-55.
19. Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 2006, 30-36.
20. Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr 2006, 96-105.
21. Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr 2006, 86-95.
22. Lee S, Zelen M A stochastic model for predicting the mortality of breast cancer. J Natl Cancer Inst Monogr 2006, 79-86.
23. Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr 2006, 56-65.
24. Holford TR, Cronin KA, Mariotto AB, Feuer EJ Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr 2006, 19-25.
25. Performance Measures for Screening Mammography Examinations from 2002 to 2006 by Age & Time (Months) Since Previous Mammography Accessed March 11, 2011. http://breastscreening.cancer.gov/data/performance/screening/2009/perf_age_time.html.
26. National Comprehensive Cancer Network NCCN Clinical Practice guidelines in oncology v.2.2008, Accessed January 2011. http://www.nccn.org/professionals/physician_gls/Lguidelines.asp.
27. Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008, 371:29-40.
28. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
29. Cronin KA, Feuer EJ, Clarke LD, Plevritis SK Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the CISNET breast cancer base case analysis. J Natl Cancer Inst Monogr 2006, 112-121.
30. Rosenberg MA Competing risks to breast cancer mortality. J Natl Cancer Inst Monogr 2006, 15-19.
31. Rosenberg RD, Yankaskas BC, Abraham LA, Sickles EA, Lehman CD, Geller BM, et al. Performance benchmarks for screening mammography. Radiology 2006, 241:55-66.
32. Fracheboud J, Groenewoud JH, Boer R, Draisma G, de Bruijn AE, Verbeek AL, et al. Seventy-five years is an appropriate upper age limit for population-based mammography screening. IntJ Cancer 2006, 118:2020-2025.
33. Mandelblatt J, Schechter C, Yabroff KR, et al. Towards optimal screening strategies for older women: Costs, benefits and harms of breast cancer screening by age, biology and health status J Gen. Intern Med 2005, 20(6):487-496.
34. McCarthy EP, Burns RB, Freund KM, Ash AS, Shwartz M, Marwill SL, et al. Mammography use, breast cancer stage at diagnosis, and survival among older women. J Am Geriatr Soc 2000, 48:1226-1233.
35. Lash TL, Fox MP, Buist DS, Wei F, Field TS, Frost FJ, et al. Mammography surveillance and mortality in older breast cancer survivors. J Clin Oncol 2007, 25:3001-3006.
36. Boer R, de Koning HJ, van Oortmarssen GJ, van der Maas PJ In search of the best upper age limit for breast cancer screening. EurJ Cancer 1995, 31A:2040-2043.
37. El Tamer MB, Ward BM, Schifftner T, Neumayer L, Khuri S, Henderson W Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg 2007, 245:665-671.
38. Bonomi AE, Boudreau DM, Fishman PA, Ludman E, Mohelnitzky A, Cannon EA, et al. Quality of life valuations of mammography screening. Qual Life Res 2008, 17:801-814.
39. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N EnglJ Med 2007, 356:1670-1674.